Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model

Figure 1 The combination therapy inhibited tumor growth (A) and improved the survival of tumor-bearing mice (B) significantly. ^aSignificant difference compared to untreated group, ^aP < 0.05.

Figure 2 Induction of auto-antibodies by cFR-1 vaccine alone or combination therapy as assessed by Western blot analysis.

Figure 3 The deposition of auto-antibodies on the endothelial cells by immunofluorescent staining (A-B) and the numbers of APBCs in spleens of mice by ELISPOT assay (C) in cFR-1 vaccine alone or combination therapy.

Figure 4 The combination therapy synergistic inhibition of angiogenesis (A) and proliferation (B), and induction apoptosis (C) at d 31 after tumor cell injection. ¹Synergistic relationship in the combination therapy (synergistic index > 1). ^aP < 0.05 vs untreated group.

Figure 5 HE staining of heart (A), liver (B), kidney (C) and lung (D) in recipient mice. No organic hemorrhage appeared in the combination therapy group and no differences were found among of C + G (a), cFR (b), G (c), and NS groups (d).